Cure My Disease

Don't miss your cure!

 Log in / Sign up

Precision radiation may boost stem cell transplant success in tough leukemias

NCT ID NCT02094794

NEW Ongoing Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 01, 2026

Summary

This study tests a precise radiation method called total marrow and lymphoid irradiation (TMLI) given with two chemotherapy drugs (etoposide and cyclophosphamide) before a donor stem cell transplant. The goal is to safely deliver higher radiation doses to the bone marrow to wipe out cancer cells while protecting nearby organs. The trial enrolls adults with high-risk acute lymphocytic or myeloid leukemia that has not responded to previous treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

total marrow and lymphoid irradiation (TMLI), cyclophosphamide, etoposide

What this could lead to

If successful, this approach could improve outcomes for patients with hard-to-treat leukemia by delivering higher radiation doses to the bone marrow while reducing side effects.

What could go wrong

This is a phase 2 trial, so results are still preliminary. The combination may still cause serious side effects, and it is not yet proven to be better than standard treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, del(5q31-q32) acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(16;16)(p13.1;q22) acute promyelocytic leukemia adult acute lymphoblastic leukemia childhood acute lymphoblastic leukemia childhood acute myeloid leukemia Congenital Abnormalities Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES ADULT ACUTE MYELOID LEUKEMIA WITH DEL(5Q) ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22) ADULT ACUTE MYELOID LEUKEMIA WITH T(15;17)(Q22;Q12) ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22) ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22) RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA RECURRENT ADULT ACUTE MYELOID LEUKEMIA RECURRENT CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010, United States